research use only
Cat.No.S1698
| Related Targets | CFTR CRM1 CD markers AChR Calcium Channel Sodium Channel Potassium Channel GABA Receptor TRP Channel ATPase |
|---|---|
| Other Chloride Channel Inhibitors | Adjudin NMD670 R(+)-Methylindazone CaCCinh-A01 Dehydroandrographolide NS1652 T16Ainh-A01 |
|
In vitro |
4-Methylpyridine : 30 mg/mL
DMSO
: 1 mg/mL
(2.87 mM)
Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 348.42 | Formula | C16H20N4O3S |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 56211-40-6 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | AC-4464, JDL-464 | Smiles | CC1=CC(=CC=C1)NC2=C(C=NC=C2)S(=O)(=O)NC(=O)NC(C)C | ||
| Targets/IC50/Ki |
Cl- channel
|
|---|---|
| In vitro |
Torsemide inhibits aldosterone secretion by adrenal cells from rats, cows, and guinea pigs stimulated in vitro by potassium, angiotensin, dibutyryl cyclic AMP, ACTH, or corticosterone. This compound's primary site of action is the thick ascending loop of Henle in the nephron, where it promotes excretion of sodium, water, and chloride via interaction with the Na+, K+, 2Cl− cotransporter. It interferes with the secretion of, and receptor ligand binding of, the mineralocorticoid aldosterone in a dose-dependent manner.
|
| In vivo |
Torsemide results in elevated levels of circulating angiotensin II and aldosterone (supportive of interference with aldosterone at the receptor level) in dogs with experimental mitral regurgitation whereas furosemide results in elevated levels of angiotensin II, only. This compound increases the BUN and plasma creatinine concentrations in rats, compared with the baseline value. It immediately increases urine volume significantly.
|
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.